CBIO vs IMNM
CBIO: Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to transform solid tumor treatment. IMNM: A clinical-stage oncology biotech advancing first-in-class and best-in-class targeted cancer therapies, including varegacestat for desmoid tumors and a pipeline of antibody-drug conjugates for solid tumors and hematologic malignancies.
Side-by-side fundamentals
| Metric | CBIO | IMNM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.83 | $22.88 | |
| Market cap as of 2026-07-23 | $615M | $2.6B | |
| Net margin as of 2026-07-23 | -990.3% | -1687.1% | CBIO higher |
| Gross margin as of 2026-07-23 | -0.5% | n/a | |
| Operating margin as of 2026-07-23 | -978.0% | -1784.1% | CBIO higher |
| ROE as of 2026-07-23 | -102.1% | -51.1% | IMNM higher |
| ROA as of 2026-07-23 | -89.3% | -47.3% | IMNM higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +413.7% | -63.3% | CBIO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -29.6% | |
| Beta as of 2026-07-23 | 1.23 | 2.11 | |
| 1-year return as of 2026-07-22 close | +26.1% | +110.5% | IMNM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.